Dexamethasone normalizes brain tumor hemodynamics as indicated by dynamic susceptibility contrast MRI perfusion parameters

Technology in Cancer Research and Treatment

Volumn 4, Issue 3, 2005, Pages 245-249

  Quarles, Christopher C ^a   Krouwer, Hendrikus G J ^a   Rand, Scott D ^a   Schmainda, Kathleen M ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

And DSC MRI; Angiogenesis; Brain tumor; Dexamethasone

Indexed keywords

DEXAMETHASONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN TUMOR; CONTROLLED STUDY; DRUG EFFECT; ECHO PLANAR IMAGING; GLIOSARCOMA; HEMODYNAMICS; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT;

EID: 20444367299     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460500400303     Document Type: Article

References (18)

1. Mendel, D. B., Laird, A. D., Xin, X. et al. In Vivo Antitumor Activity of SU11248, A Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Facto Receptors: Determination of Pharmacokinetic/Pharmacodynamic Relationship. Clinical Cancer Research 9, 327-337 (2003).
2. Gorski, D., Mauceri, J. H., Salloum, R. M. et al. Prolonged Treatment with Angiostatin Reduces Metastatic Burden During Radiation Therapy. Cancer Research 63, 308-311 (2003).
3. Machein, M. R., Kullmer, J., Ronicke, V. et al. Differential Downregulation of Vascular Endothelial Growth Factor by Dexamethasone in Normoxic and Hypoxic Rat Glioma Cells. Neuropathology and Applied Neurobiology 25, 104-112 (1999).
4. Badruddoja, M. A., Krouwer, H. G. J., Rand, S. D. et al. Antiangiogenic Effects of Dexamethasone in 9L Gliosarcoma Assessed by MRI Cerebral Blood Volume Maps. Neuro-Oncology 5, 235-243 (2003).
5. Jain, R. K. Normalizing Tumor Vasculatrue with Anti-angiogeneic Therapy: A New Paradigm for Combination Therapy. Nature Medicine 7, 987-989 (2001).
6. Ansiaux, R., Baudelet, C., Jordan, B. et al. Changes in the Tumor Microenvironment Early After Treatment with the Anti-angiogenic Agent Thalidomide. Proceedings of the 11th Annual Meeting of ISMRM, Kyoto, Japan, (2004).
7. Donahue, K. M., Krouwer, H. G. J., Rand, S. D. et al. Utility of Simultaneously Acquired Gradient-echo and Spin-echo Cerebral Blood Volume and Morphology Maps in Brain Tumor Patients. Magnetic Resonance in Medicine 43, 845-853 (2000).
8. Boxerman, J. L., Hamberg, L. M., Rosen, B. R. et al. MR Contrast Due to Intravascular Magnetic Susceptibility Perturbations. Magnetic Resonance in Medicine 34, 555-566 (1995).
9. Ostergaard, L., Weisskoff, R. M., Chesler, D. A. et al. High Resolution Measurement of Cerebral Blood Flow using Intravascular Tracer Bolus Passages. Part I: Mathematical Approach and Statistical Analysis. Magnetic Resonance in Medicine 36, 715-725 (1996).
10. Ostergaard, L., Chesler, D. A., Weisskoff, R. M. et al. Modeling Cerebral Blood Flow and Flow Heterogeneity from Magnetic Resonance Residue Data. Journal of Cerebral Blood Flow and Metabolism 19, 690-699 (1999).
11. Gillies, R. J., Schornack, P. A., Secomb, T. W. et al. Causes and Effects of Heterogeneous Perfusion in Tumors. Neoplasia 1, 197-207 (1999).
12. Ostergaard, L., Hochberg, F. H., Rabinov, J. D. et al. Early Changes Measured by Magnetic Resonance Imaging in Cerebral Blood Flow, Blood Volume, and Blood-brain Barrier Permeability Following Dexamethasone Treatment in Patients with Brain Tumors. J. Neurosurg. 90, 300-305 (1999).
13. Van Roost, D., Hartmann, A., and Quade, G. Changes of Cerebral Blood Flow Following Dexamethasone Treatment in Brain Tumour Patients. A Xe/CT Study. Acta Neurochir. (Wien). 143, 37-43; Discussion 43-44 (2001).
14. Swaroops, G. R., Kelly, P. A., Holmes, M. C. et al. The Effects of Dexamethasone Therapy on Permeability, Blood Flow and iNOS Expression in Experimental Glioma. Journal of Clinical Neuroscience 8, 35-39 (2001).
15. Silva, A. C., Kim, S. G., and Garwood, M. Imaging Blood Flow in Brain Tumors using Arterial Spin Labeling. Magnetic Resonance in Medicine 44, 169-173 (2000).
16. Tong, R. T., Boucher, Y., Kozin, S. V. et al. Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors. Cancer Research 64, 3731-3736 (2004).
17. Browder, T., Butterfield, C. E., Kraling, B. M. et al. Antiangiogenic Scheduling of Chemotherpay Improves Efficacy Against Experimental Drug-resistant Cancer. Cancer Research 60, 1878-1886 (2000).
18. Griffin, R. J., Williams, B. W., Wild, R. et al. Simultaneous Inhibition of the Receptor Kinase Activity of Vascular Endothelial, Fibroblast, and Platelet-derived Growth Factors Suppresses Tumor Growth and Enhances Tumor Radiation Response. Cancer Research 62, 1702-1706 (2002).